Hepatitis C (chronic) - sofosbuvir: evaluation report
01 - Pre-Meeting Briefing prepared by NICE
02 - Submission from the technology manufacturer - Gilead Sciences
03 - Extract from the appendices to the manufacturer's submission - Gilead Sciences
04 - NICE request to the manufacturer for clarification on their submission
05 - Manufacturer clarification response
06 - Consultee submission - British HIV Association and British Association for Sexual Health and HIV
07 - Consultee submission - Hepatitis C Trust
08 - Consultee submission - Royal College of Nursing
09 - Clinical expert personal perspective - Aspinall
10 - Patient expert personal perspective - Gore
11 - Clinical expert personal perspective - Jacobs
12 - Patient expert personal perspective - Zapletal
13 - Evidence Review Group report prepared by Southampton Health Technology Assessments Centre (SHTAC)
14 - Erratum to the Evidence Review Group report prepared by Southampton Health Technology Assessments Centre (SHTAC)
15 - Manufacturer factual accuracy check of Evidence Review Group report
16 - Exploratory analyses prepared by Southampton Health Technology Assessments Centre (SHTAC)
Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.
It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.
If you have any feedback on the new format please contact the Project Manager for this appraisal.
Hepatitis C (chronic) - sofosbuvir: evaluation report
16 June 2014 (10.52 Mb 17 sec) |
This page was last updated: 20 June 2014